Extracellular matrix and integrin receptor system (ECM-Integrin system)

The host tissue extracellular matrix (ECM) and cellular integrins form a fundamental bidirectional signaling and structural unit that governs cell behavior and tissue architecture (Hynes, 2002 [1]; Frantz et al., 2010 [3]). The ECM is a complex meshwork of fibrous proteins, glycoproteins, and proteoglycans that provides physical support and biochemical cues to cells (Frantz et al., 2010 [3]). Integrins are the primary transmembrane receptors that mediate cell attachment to the ECM, functioning as heterodimers composed of alpha and beta subunits (Campbell & Humphries, 2011 [2]). This interaction is critical for mechanotransduction, allowing cells to sense and respond to the physical properties of their environment, which in turn regulates processes such as cell migration, proliferation, and survival (Hynes, 2002 [1]; Ley et al., 2016 [4]). Dysregulation of the ECM-integrin axis is a hallmark of various pathologies, including cancer metastasis, where it facilitates tumor cell invasion, and fibrosis, where excessive ECM accumulation impairs organ function (Frantz et al., 2010 [3]; Ley et al., 2016 [4]). Consequently, this system is a major focus for therapeutic intervention, with drugs targeting specific integrins to treat conditions ranging from autoimmune diseases to cardiovascular disorders (Ley et al., 2016 [4]).

Other names

Cell-matrix adhesion complexECM-integrin axisIntegrin-mediated adhesion systemHost tissue ECM and integrins

Drugs targeting this system primarily act by competitively inhibiting the binding of extracellular matrix ligands (such as fibronectin, laminin, or vitronectin) to specific integrin heterodimers on the cell surface (Hynes, 2002 [1]; Ley et al., 2016 [4]). This blockade prevents cell-matrix adhesion and disrupts the "outside-in" signaling pathways that drive pathological processes like leukocyte extravasation in inflammation or platelet aggregation in thrombosis (Campbell & Humphries, 2011 [2]; Ley et al., 2016 [4]).